It's a positive from me. I'll be interested to see the cash balance and hopefully the cash burn is reduced and they have another 6-12 months to improve the retail marketing. At least there is some monetary value attached albeit by a stake in the company. I interpret another avenue outside waiting for a big pharma to buy/invest in the current DEP candidates. I'll await the May webinar which will be enlightening to see how much Cheryl has diverged from previous Management and strategy. Small mercies.
SPL Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
